Cibinqo (abrocitinib) / Pfizer, Glenmark - LARVOL DELTA

Long-Term Efficacy of Abrocitinib For Atopic Dermatitis: 96 Week Results of the JADE EXTEND Study Comparing Patients Receiving Monotherapy With Those Receiving Combination Therapy Including Topical Medications. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Monotherapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Sustained effectiveness of upadacitinib and abrocitinib in moderate-to-severe atopic dermatitis: a 104-week, real-world, retrospective study (EADV 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Pediatric Alopecia Areata and JAK Inhibitors: Bridging the Gap Between Evidence and Practice. (PubMed, J Am Acad Dermatol) - "Despite this, emerging evidence and clinical experience demonstrate meaningful hair regrowth in pediatric patients treated with several JAKis, including abrocitinib, baricitinib, deuruxolitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib, with generally favorable safety profiles. Limitations include heterogeneous outcome reporting between various reports and studies. Overall, this clinical review synthesizes current evidence and clinical experience to provide practical guidance on JAKi selection, dosing, safety monitoring, and key considerations for implementing these therapies in pediatric AA."

Journal • Review • Alopecia • Eosinophilia • Gastrointestinal Disorder • Immunology • Pediatrics

Upadacitinib versus abrocitinib in atopic dermatitis: a propensity score-adjusted comparison from BioDay (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis. (PubMed, J Am Acad Dermatol) - "JAK inhibitors may be a reasonable option for carefully selected older adults, but the decision should be a deliberate one. It rests on disease-specific efficacy, baseline cardiovascular and oncologic risk, modifiable comorbidities, label-directed dosing, and close monitoring. Age-stratified data remain sparse, and each decision should be individualized."

Journal • Review • Alopecia • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Differential Proteomic Effects of Abrocitinib and Dupilumab in Moderate-to-Severe Atopic Dermatitis: Exploratory Analysis of JADE COMPARE (EADV 2026) - No abstract available

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy of abrocitinib and dupilumab on chronic hand eczema in patients with moderate-to-severe atopic dermatitis: a prespecified exploratory analysis of the phase 3 JADE DARE study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • P3 data • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report. (PubMed, Front Immunol) - "In contrast, dupilumab provides sustained disease control by inhibiting IL-4/IL-13-mediated Th2 responses, reducing eosinophilic inflammation and autoantibody production. This case highlights a complementary therapeutic strategy integrating rapid disease control with long-term immune modulation, suggesting that our bridging therapy may represent a rational and effective approach for patients with bullous pemphigoid with insufficient response to initial corticosteroid therapy, warranting further investigation in controlled studies."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immune Modulation • Immunology • Inflammation • Pruritus • IL13 • IL4 • JAK1

Abrocitinib modulates multi-axis immune activation in moderate-to-severe AD patients who failed Dupilumab (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Real-world treatment patterns and effectiveness of abrocitinib in atopic dermatitis: Interim results on Abrocitinib Chinese rEgistry on AD (AHEAD) (EADV 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Abrocitinib in the Treatment of Acquired Reactive Perforating Collagenosis Associated with Diabetes Mellitus: Two Case Reports (EADV 2026) - No abstract available

Case report • Clinical • Diabetes • Metabolic Disorders

JAK1 Inhibition With Abrocitinib in Refractory Prurigo Pigmentosa Following Multiple Vaccinations (EADV 2026) - No abstract available

JAK1

Real-world abrocitinib dose adjustments and treatment patterns vary by prior treatment history and line of therapy in adults with moderate-to-severe atopic dermatitis (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Interim Analysis of the ATTRACT Registry: Real-World Treatment Patterns and Clinical Outcomes of Abrocitinib at Week 52 in Moderate-to-Severe Atopic Dermatitis in Taiwan (EADV 2026) - No abstract available

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Objective assessment of nocturnal scratching and sleep impairment using accelerometry in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: results from ADAIR (Treating Atopic Dermatitis with Abrocitinib and its Impact in Real Life) study (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Short- and long-term efficacy of abrocitinib in atopic dermatitis in a real-world longitudinal study (EADV 2026) - No abstract available

Clinical • Longitudinal study • Observational data • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy Outcomes of Abrocitinib in Adult Patients With Moderate-to-Severe Atopic Dermatitis Using Canadian Treat-to-Target Criteria (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

On-Treatment Complete Disease Control Attainment With Abrocitinib (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Pre- and Post-Abrocitinib Treatment Journey in Patients with Atopic Dermatitis: Real-World Evidence from the DREAM TO TREAT AD (D2T AD) Consortium (EADV 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Abrocitinib reduces pathogenic skin-resident memory T cells and restores barrier integrity in atopic dermatitis: a biopsy-based analysis from the JADE MOA trial (EADV 2026) - No abstract available

Biopsy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-world experience of abrocitinib for atopic dermatitis: A 16-week multicenter retrospective study (EADV 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Abrocitinib Recapture to On-Drug Complete Disease Control and Very Low Disease Activity Thresholds (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

A biomarker of type VII collagen degradation is correlated with EASI and decreases after 12 weeks of abrocitinib and baricitinib treatment in patients with atopic dermatitis (EADV 2026) - No abstract available

Biomarker • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-to-Severe Atopic Dermatitis: Final Data From More Than >9600 Patient-Years With Up to 6.5 Years of Exposure (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Impact of Disease Duration on Clinical Responses and Short-Term Safety With Abrocitinib Combination Therapy in Patients With Moderate-to-Severe Atopic Dermatitis (EADV 2026) - No abstract available

Clinical • Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology